Trastuzumab emtansine as a preferred second-line choice after horizontal dual blockade

NewsGuard 100/100 Score

Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.

HER2 signaling conditions tumor behavior and treatment strategies of HER2 expressing breast cancer.

Cancer treatment guidelines uniformly identify dual blockade with pertuzumab and trastuzumab plus a taxane as best first line and trastuzumab emtansine as a preferred second-line choice.

However, there is no prospectively designed available study focusing on the sequence and outcomes of patients treated with T-DM1 following the triplet.

In the following report, data concerning a wide series of patients treated in a real-life setting are presented.

Results obtained in terms of response and median progression-free survival suggests a significant role for T-DM1 in disease control of metastatic HER2 expressing breast cancer.

From the 80s, Human Epidermal Growth Factor Receptor 2 (HER2) signaling was increasingly recognized as pivotal in tumor growth of HER2 expressing breast cancer. HER2 expression is limited to a proportion (15-20%) of breast cancer; however, HER2 conditions tumor behavior and addresses treatment strategies."

Dr. Salvatore Del Prete from the Medical Oncology Unit "San Giovanni di Dio" Hospital, Frattamaggiore and Dr. Liliana Montella from the Medical Oncology Unit "Santa Maria delle Grazie" Hospital

Currently available guidelines in metastatic HER2 positive breast cancer design a sequence of treatment with first-line double blockade with trastuzumab plus pertuzumab and a taxane according to Cleopatra trial results and second-line treatment with trastuzumab emtansine enforced by Emilia trial results and, then, lapatinib plus capecitabine.

The reduced toxicity of T-DM1 in the second and later lines of treatment together and the high rates of activity and efficacy are determinant in choosing treatment for a patient candidate to a prolonged time on treatment.

On February 22, 2013, the Food and Drug Administration approved T-DM1 for use as a single agent in the treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane.

Such results induced FDA on May 3, 2019, to approve T-DM1 for the adjuvant treatment of patients with HER2-positive early breast cancer treated with neoadjuvant taxane and trastuzumab-based treatment and having a residual invasive disease in the breast or axilla at the surgery .

In the present study, data coming from different centers concerning patients with HER2 positive metastatic breast cancer treated with second-line T-DM1 following trastuzumab and pertuzumab were collected and evaluated.

The Del Prete/Montella Research Team concluded in their Oncotarget Research Article that despite the increased rate of survival of metastatic breast cancer patients overall, a rate of patients is lost at any line of therapy.

In two different studies concerning patients series treated predominantly before 2010, 3% and 26% of patients reached the goal of third-line treatment.

This evidence underscores the need to give our patients the best treatment as early as possible.

Summarizing, the available evidence is substantially in favor of the choice of T-DM1 in the treatment of HER2 breast cancer at second and later lines.

Journal reference:

Del Prete, S., et al. (2020) Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lurie Children's Hospital administers first gene therapy for Duchenne muscular dystrophy in Illinois